AR101
Aimmune’s peanut allergy therapy closes in on approval with promising Phase 3 data
March 26, 2019Manufacturing and Production, Research and Development AR101, Aimmune, allergy, pharma
Aimmune Therapeutics is gearing up for regulatory review of its investigational food allergy therapy AR101 following the release of new …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
